ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
ArriVent BioPharma Inc

ArriVent BioPharma Inc (AVBP)

27.645
0.235
( 0.86% )
Updated: 03:51:17

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
27.645
Bid
27.53
Offer
27.74
Volume
79,168
27.00 Day's Range 27.81
14.35 52 Week Range 36.37
Market Cap
Previous Close
27.41
Open
27.56
Last Trade
1
@
27.57
Last Trade Time
03:53:01
Financial Volume
US$ 2,168,739
VWAP
27.3941
Average Volume (3m)
277,226
Shares Outstanding
33,697,161
Dividend Yield
-
PE Ratio
-13.39
Earnings Per Share (EPS)
-2.06
Revenue
-
Net Profit
-69.33M

About ArriVent BioPharma Inc

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therap... ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
ArriVent BioPharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVBP. The last closing price for ArriVent BioPharma was US$27.41. Over the last year, ArriVent BioPharma shares have traded in a share price range of US$ 14.35 to US$ 36.37.

ArriVent BioPharma currently has 33,697,161 shares in issue. The market capitalisation of ArriVent BioPharma is US$923.64 million. ArriVent BioPharma has a price to earnings ratio (PE ratio) of -13.39.

AVBP Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.055-12.791798107331.731.726.418868327.505365CS
4-2.545-8.4299436899630.1936.3726.414575231.06619966CS
120.3551.3008427995627.2936.3722.327722626.54802005CS
267.99540.687022900819.6536.3715.5317530425.33863506CS
523.64515.18752436.3714.3517821822.90820523CS
1563.64515.18752436.3714.3517821822.90820523CS
2603.64515.18752436.3714.3517821822.90820523CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
US$ 2.07
(111.22%)
110.56M
CRNCCerence Inc
US$ 4.675
(65.78%)
35.57M
QUBTQuantum Computing Inc
US$ 5.095
(38.45%)
92.52M
SPAISafe Pro Group Inc
US$ 4.4123
(37.88%)
37.01M
IBGInnovation Beverage Group Limited
US$ 1.06
(33.97%)
9.6M
GLXGGalaxy Payroll Group Ltd
US$ 1.51
(-61.38%)
1.01M
PYXSPyxis Oncology Inc
US$ 2.10
(-45.03%)
10.14M
KURAKura Oncology Inc
US$ 9.92
(-37.65%)
8.27M
BLRXBioLineRx Ltd
US$ 0.355
(-34.89%)
6.39M
TMTCTMT Acquisition Corporation
US$ 4.52
(-29.81%)
18.84k
CDTConduit Pharmaceuticals Inc
US$ 0.112951
(22.37%)
499.7M
NVDANVIDIA Corporation
US$ 144.855
(-0.71%)
212.11M
AKTSAkoustis Technologies Inc
US$ 0.0985
(13.09%)
185.68M
ELABElevai Labs Inc
US$ 0.0201
(-6.07%)
175.91M
WORXSCWorx Corporation
US$ 2.07
(111.22%)
110.56M